Influence of inflammatory and non-inflammatory rheumatic disorders on the clinical and biological profile of type-2 diabetes
| Autor: | Yannick Allanore, Etienne Larger, Florent Eymard, Frédéric Banal, Anna Molto, Muriel Elhai, Marine Forien, Joël Damiano, Jérôme Avouac, Philippe Dieudé, Jérémie Sellam |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Type 2 diabetes Systemic inflammation Gastroenterology Arthritis Rheumatoid Insulin resistance Rheumatology Internal medicine Diabetes mellitus Osteoarthritis medicine Blood test Humans Hypoglycemic Agents Pharmacology (medical) Aged Aged 80 and over medicine.diagnostic_test business.industry Odds ratio Middle Aged medicine.disease Cross-Sectional Studies Diabetes Mellitus Type 2 Metabolic control analysis Rheumatoid arthritis Antirheumatic Agents Female medicine.symptom Insulin Resistance business |
| Zdroj: | Rheumatology (Oxford, England). 60(8) |
| ISSN: | 1462-0332 |
| Popis: | Objective To study the profile of type-2 diabetes (T2D) in patients with RA or OA. Methods This observational, multicentre, cross-sectional study included, over a 24-month period, consecutive patients with adult-onset diabetes and RA or OA. We collected demographics, disease activity and severity indices, current treatments for RA and diabetes, history and complications of diabetes. A systematic blood test was performed, assessing inflammatory, immunological and metabolic parameters. The homoeostasis model assessment (HOMA)2-S was used to assess insulin resistance. Results We included 167 patients with T2D, 118 with RA and 49 with OA. RA and OA patients had severe T2D with suboptimal metabolic control and a biological profile of insulin resistance. Insulin resistance was significantly higher in RA than in OA patients after stratification on age, BMI and CS use [HOMA2-S: 63.5 (35.6) vs 98.4 (69.2), P Conclusion RA patients display severe T2D with inflammation-associated insulin resistance. These findings may have therapeutic implications, with the potential targeting of insulin resistance through the treatment of joint and systemic inflammation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|